Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients.

Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific membrane antigen- (PSMA) positron emission tomography/computed tomography (PET/CT) and ferumoxtran-10 nanoparticle-enhanced magnetic resonance imaging (nano-MRI) are imaging modalities with high potential to identify LN metastases in PCa patients.